HISTAFED COMPOUND LINCTUS

This brand name is authorized in Israel

Active ingredients

The drug HISTAFED COMPOUND LINCTUS contains a combination of these active pharmaceutical ingredients (APIs):

1 Triprolidine
UNII YAN7R5L890 - TRIPROLIDINE HYDROCHLORIDE
2 Pseudoephedrine
UNII 6V9V2RYJ8N - PSEUDOEPHEDRINE HYDROCHLORIDE

Pseudoephedrine is a sympathomimetic agent with direct and indirect effects on adrenergic receptors. It has alpha and beta adrenergic activity and some stimulant effect on the central nervous system. The sympathomimetic effect of pseudoephedrine produces vasoconstriction which in turn relieves nasal congestion.

Read about Pseudoephedrine
3 Codeine
UNII GSL05Y1MN6 - CODEINE PHOSPHATE

Codeine is a centrally acting weak analgesic. Codeine exerts its effect through μ opioid receptors, although codeine has low affinity for these receptors, and its analgesic effect is due to its conversion to morphine. Codeine, particularly in combination with other analgesics such as paracetamol, has been shown to be effective in acute nociceptive pain. The anti-tussive activity of codeine is probably due to its depressant effect on the medullary cough centre in the brain.

Read about Codeine

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 2191

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.